The company aims to create, isolate and characterise the highest value cells for biological medicine development
Solentim has launched a dedicated workflow for single cell cloning of human induced pluripotent stem cells (hiPSCs).
The company’s VIPS (verified in-situ plate seeding) is used for single cell cloning of CHO and HEK manufacturing cell lines in combination with the company’s InstiGRO growth supplements. Its repertoire has now been extended to include hiPSC cells to address the industry challenges of poor clone viability after single cell seeding, a lack of standardization for assurance between labs and for documentation of clonality.
The VIPS can deliver around 80% seeding efficiency and allows for high viability and outgrowth of stem cell colonies due to the gentle seeding method in combination with MatriClone, an animal component-free matrix used in solution at the time of seeding.
The VIPS is then able to track the single cell origin and progression to a colony using daily whole well imaging and provide a clonality report which can be supplied to a regulator as part of an IND submission.
Mark Truesdale, CEO, Solentim, commented: “The combination of the VIPS and MatriClone soluble matrix is a significant workflow improvement for customers doing cell reprogramming or gene editing of iPSCs. We are delighted to be able support the fast-growing use of stem cells in both research, such as disease models, as well as in the advancement of stem cell therapies, such as the very exciting field of allogeneic cell therapy.”
Dr Truesdale added, “our existing Cell Metric customers can also purchase MatriClone and immediately begin to demonstrate the benefits for their existing iPSC projects.”
Solentim is also working to support customers in future manufacturing by implementing a GAMP-5 policy. Dr Truesdale commented, “We have always placed quality as a central pillar in our work. With our new GAMP-5 policy, we look to further integrate with our customer’s GMP requirements as they move towards the development of stem cell therapies.”